Pharmaceuticals GW Pharmaceuticals PLC (OTC: GWPRF) is an innovative pharmaceutical developer that focuses on CBD (cannabidiol) therapies. It was the first company to receive FDA approval for a cannabis-based drug, and it’s close to releasing its second CBD treatment. Low earnings and hesitation during the COVID19 pandemic have left this stock lingering at the bottom of the market. However, analysts are confident of an upside.

This pharmaceuticals company is in the last stage of trials for its Nabiximols drug, a novel treatment for Multiple Sclerosis. Like the company’s novel epilepsy treatment, the release of this drug could drive revenue to new levels.

This stock is highly speculative, but top analysts are convinced that existing treatments and those in the pipeline will result in massive long-term earnings growth. When the company reported its first-quarter earnings this year, sales were at $120.6 million, more than tripling the $39.2 million reported the year before. Out of 16 analysts reported by FactSet, 15 recommend a BUY rating. The average target price of $190.69 suggests incredible growth for investors willing to wait for GW’s pipeline drugs to generate new revenue.

Bargain investing is heavily based on risk and speculation. A small holding in this affordable stock could create strong returns in the future.

Key Data:

  • 1 Year Price Growth: -27.77%
  • YTD Price Growth: 02%
  • 3 Month Price Growth: -4.23%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.